FindTrial
Sign In

Camrelizumab Plus Chemotherapy

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University, Shandong Cancer Hospital and Institute

Conditions

Biomarkers / BloodIMMUNOTHERAPYNeoadjuvant TherapyResectable Lung Non-Small Cell CarcinomaTNBC - Triple-Negative Breast CancerTriple Negative Breast Cancer

Phase 2

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
RecruitingNCT06241807
Shandong Cancer Hospital and InstituteBiomarkers / Blood, IMMUNOTHERAPY, Neoadjuvant Therapy +1
Start: 2022-12-02End: 2026-12-31Target: 30Updated: 2024-02-14

Phase 3

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
CompletedNCT04613674
Jiangsu HengRui Medicine Co., Ltd.Triple Negative Breast Cancer
Start: 2020-12-09End: 2024-03-05Updated: 2024-03-27
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
RecruitingNCT05999149
Fudan UniversityTNBC - Triple-Negative Breast Cancer
Start: 2023-08-20End: 2027-08-30Target: 424Updated: 2024-02-21

Related Papers

Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study.
2026-06-19
Abstract GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial
Clinical Cancer Research2025-06-131 citations
Molecular imaging using <sup>18</sup>F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB NSCLC.
2025-05-10
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
JAMA2024-12-1332 citations
Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.
Journal of Clinical Oncology2024-06-011 citations
Abstract PO2-13-04: Single cell characterization of senescent CD8+ T cell promotes immunotherapy resistance in early-stage triple-negative breast cancer
Cancer Research2024-05-02
Abstract PO1-15-09: Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2- Breast Cancer
Cancer Research2024-05-02
Abstract PO1-14-07: Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial)
Cancer Research2024-05-02
Abstract PD4-05: PD4-05 Integrated multi-cohort profiling identifies CCL19+ dendritic cells to potentiate immunotherapy efficacy in triple-negative breast cancer
Cancer Research2023-03-01